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Abstract
Objective. To gain insight into clinical practice regarding referral, early diagnosis and other aspects of the
management of patients with dcSSc in Europe and the USA.
Methods. Semi-structured interviews were conducted with 84 rheumatologists (or internal medicine phys-
icians) and 40 dermatologists in different countries (the UK, France, Germany, Italy, Spain and the USA).
Physicians were asked to identify key steps in the patient pathway relating to patient presentation, diag-
nosis and referral, in addition to other treatment and follow-up processes.
Results. The interviewed physicians reported that late presentation with dcSSc was common, with some
patients presenting to primary care physicians after symptoms had persisted for up to 1 year. Awareness
of dcSSc is reported to vary widely among primary care physicians. Final diagnosis, generally following
guideline-based recommendations, was by rheumatologists in most cases (or internal medicine physicians
in France) and they remained responsible for global patient management, with lesser involvement in
diagnosis and management by dermatologists. Specialist centres were not well defined and did not
exist in all countries.
Conclusion. Patients and primary healthcare providers can be unaware of the symptoms of dcSSc,
therefore presentation and referral to specialist care are often late. Thus, improved awareness among
patients and primary care physicians is necessary to facilitate earlier referral and diagnosis. Once referred,
more consistent use of the modified Rodnan skin score at diagnosis and follow-up may help to monitor
disease progression. Furthermore, establishing specialist centres may help to promote such changes and
improve patient care.
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Rheumatology key messages
. Lack of disease awareness in dcSSc patients and primary physicians can delay referral to specialists.
. Identification of specialist centres may lead to improved patient care in dcSSc.
. Consistent use of validated tools may help to monitor disease progression in dcSSc.
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Introduction
SSc is a rare multi-organ autoimmune rheumatic disease
with high mortality, particularly in patients with dcSSc [16].
Timely referral to SSc centres and early diagnosis of organ
manifestations are essential to allow intervention before
organ damage occurs [7]. Indeed, organ involvement is
observed early in dcSSc and is often already present
when patients are seen at expert centres [6]. This highlights
the urgent need for an improved referral process. For ex-
ample, in RA the importance of early diagnosis and referral
to improve long-term morbidity and mortality is well estab-
lished [8]. There is, however, little knowledge of how pa-
tients with dcSSc are managed early in their disease. Better
understanding of routine management is necessary to
improve the early referral process.
Methods
The objective of this research was to gain insights into the
real-world referral, diagnosis, treatment and follow-up of pa-
tients with dcSSc in Europe and the USA. This was achieved
through semi-structured interviews of treating physicians
from the UK, France, Germany, Italy, Spain and the USA.
To be eligible, rheumatologists and internal medicine
(IM) physicians needed a caseload of 15 patients or
more with SSc and 4 or more with dcSSc; dermatologists
were required to have 10 patients or more and 3 patients
or more, respectively. Only one physician from each
centre could participate in the study. To ensure represen-
tation of different practice settings, physicians were re-
cruited from specialist centres (defined as those who
were participating in SSc trials or members of associated
networks) as well as other hospital or office-based set-
tings. Each physician participated in a 30-min (dermatolo-
gists) or 60-min (rheumatologists and internists) interview
that followed a discussion outline (see supplementary
data, available at Rheumatology online). Physicians were
asked to identify key steps in the patient pathway, that is,
typical patient presentation to the primary healthcare pro-
vider (HCP), specialist referral, the diagnostic process,
approaches to treatment and disease evaluation.
Physicians were also asked who was responsible for
implementing each step.
All research materials (see supplementary data, avail-
able at Rheumatology online) were designed by a team
(led by S.D.) with extensive experience in qualitative and
quantitative research in specialist medical indications. All
analyses and the interpretation were conducted by the
same team. One member of the team read the transcripts
for each country, and a five-step analysis process
adapted from Ereaut [9] was adopted (see supplementary
data, available at Rheumatology online).
Participants
The sample of rheumatologists (including IM physicians in
France) was designed to provide a small-scale, qualitative
overview to determine the appropriate sample composition
for an anticipated larger survey. The target sample was
15 physicians per country. When structured to ensure
responses from a range of different practice settings, this
would provide a sufficient breadth of perspective and a
reasonable expectation that key features and issues in
SSc referral, diagnosis and management would emerge.
As skin changes are an early manifestation of SSc,
dermatologists often play a role in patient identification,
diagnosis and referral. Furthermore, a minority of centres
in each country are based in dermatology clinics.
Therefore, we sampled seven dermatologists per country
to allow sufficient representation of those who work in
SSc centres and those who do not.
Results
Eighty-four 60-min interviews were conducted with rheuma-
tologists in the UK, France, Germany, Italy, Spain and the
USA, and IM physicians in France (Table 1). Forty 30-min
interviews were conducted with dermatologists (Table 1).
Primary care: presentation and referral
Late presentation was commonly reported; patients with
dcSSc generally presented to their primary HCP after
symptoms had persisted for up to 1 year, depending on
severity. Patients with severe symptoms, such as digital
ulcers, breathing problems or renal issues, presented im-
mediately, while patients with RP typically presented after
39 months. Physicians stated that patients often con-
sidered early symptoms (e.g. gastrointestinal reflux, cold
fingers, mild skin thickening and fatigue) not to be serious
enough to justify medical attention, and patients initially
made lifestyle modifications to accommodate them. The
symptoms most commonly prompting patients to visit a
primary HCP were skin and vascular complications, such
as RP, skin thickening and puffy fingers (Fig. 1). Further
information on physician perceptions of dcSSc awareness
among primary HCPs is included as supplementary data,
available at Rheumatology online.
Physicians reported that awareness of dcSSc among pri-
mary HCPs varied widely, and that primary HCPs may not
immediately associate common symptoms, such as RP,
with dcSSc, resulting in slow or inappropriate referrals and
delayed diagnosis. This was more commonly noted by
rheumatologists (25/84; 30%) than dermatologists (5/40;
13%), who more frequently noted that primary HCPs will
refer patients to them with skin problems such as RP, but
are unlikely to suspect dcSSc. It was also noted by 8/84
rheumatologists (10%) that when a combination of symp-
toms is apparent, primary HCPs are more likely to consider
a systemic condition and request antibody testing, which
leads to a correct referral. In all countries, at least one
rheumatologist noted that patients experienced delayed
referral as a result of waiting lists to see a specialist.
Specialist care
Specialist centres
There are no formal definitions or accreditations for special-
ist SSc centres in most countries. However, the physicians
interviewed identified what they considered to be specialist
centres based on high patient caseloads, multidisciplinary
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team management, trial involvement and the presence of
individual physicians with a known interest in SSc.
Diagnosis
Final diagnosis was made by rheumatologists (and IM
physicians in France) in most cases. In Germany,
France and Italy, dermatologists also provided the diag-
nosis (Fig. S1, available as supplementary data at
Rheumatology online). In all countries, dermatologists’
caseloads were 1151% greater than those of rheuma-
tologists or IM physicians (Table 1). The dcSSc diagnosis
was less frequently made by pulmonologists, followed
by angiologists (Germany/France) or primary HCPs (who
referred patients with a highly suspected diagnosis).
Diagnosis was based on signs and symptoms (e.g. skin
thickening on proximal extremities and trunk, and skin
tightening around the mouth), and was confirmed with in-
vestigations such as autoantibody tests and nail-fold
capillaroscopy. Physicians were confident that in many
cases a rapid and accurate diagnosis could be made in
this way without further evaluation. Supplementary tests
(e.g. digital skin perfusion, skin biopsy, angiography or
hand/foot X-ray) were used when other assessments
were inconclusive.
Although classification guidelines were not followed rigidly,
physicians reported routine diagnostic processes (Fig. S2,
available as supplementary data at Rheumatology online)
that reflected the ACR/EULAR classification of SSc [10].
Fig. S3, available as supplementary data at Rheumatology
online, shows the most commonly reported complications.
Physicians were highly vigilant for organ complications at
diagnosis and at follow-up.
Treatment
Rheumatologists (and IM physicians in France) reported
being the central co-ordinator of ongoing care for most
patients, responsible for global management throughout
the patient’s disease course, with support from relevant
specialists for organ-specific complications.
The main treatment goals reported were to limit organ
involvement and/or progression, limit skin progression,
and relieve symptoms or improve patients’ quality of life.
Treatment choices tended to be tailored to the presenting
complications. For example, where interstitial lung dis-
ease is present, the systemic therapy of choice for skin
complications is likely to be MMF.
Most physicians were unsatisfied with current treatment
options. Primary concerns were related to limiting organ
complications, with skin complications—a priority for pa-
tients—recognized as being particularly poorly managed.
Treatments for skin complications were also a priority for
dermatologists. The supplementary data, available at
Rheumatology online, gives further details of physician
responses regarding treatment.
Follow-up
Patients with stable disease generally received follow-up
assessments by rheumatologists every 36 months
unless rapid progression dictated more frequent interven-
tion (50/59 rheumatologists; 85%), with 8/59 rheumatolo-
gists (14%) stating that they followed up more regularly.
Physicians said they relied on regular screening to identify
organ involvement, in addition to asking about new symp-
toms during routine visits.
The modified Rodnan skin score (mRSS) [11] was most
commonly used by rheumatologists (and IM physicians in
France) (Table S1 available as supplementary data at
Rheumatology online). Of note, 8 rheumatologists (10%)
and 18 dermatologists (45%) were unaware of the mRSS.
Where the mRSS was measured, physicians expected
>50% of diagnosed patients would have an mRSS
515. Further details of testing for organ complications,
and the involvement of other specialists and general prac-
titioners in patient follow-up, are included in the supple-
mentary data, available at Rheumatology online.
Physicians believed that, after diagnosis, most patients
were well informed about their disease state. Patients
were provided with information or support about their
condition, including leaflets, website addresses, tele-
phone helplines and support groups. However, awareness
of patient associations was relatively low.
Discussion
Early detection of SSc and its complications is critical to
allow early intervention and prevent progression [7]. With
TABLE 1 Characteristics of physicians interviewed for the study
Characteristics of physicians UK France Germany Italy Spain USA Total
Rheumatologists/IM physicians, n 11/0 7/8 15/0 15/0 13/0 15/0 76/8
SSc patient caseload, mean (S.D.) 140 (134) 84 (119) 86 (68) 65 (72) 39 (33) 214 (229) 104 (137)
LcSSc 89 (95) 52 (82) 40 (41) 33 (49) 25 (27) 124 (144) 60 (88)
DcSSc 50 (48) 32 (48) 45 (36) 32 (32) 15 (8) 89 (94) 44 (56)
Duration of specialization, mean (S.D.), years 14 (6) 17 (7) 12 (6) 10 (4) 18 (6) 19 (9) 15 (7)
Dermatologists, n 7 7 7 7 5 7 40
SSc patient caseload, mean (S.D.) 34 (31) 18 (8) 44 (41) 11 (2) 11 (2) 24 (18) 24 (25)
LcSSc 19 (16) 12 (6) 27 (25) 7 (2) 5 (3) 16 (17) 15 (16)
DcSSc 16 (16) 7 (3) 17 (17) 5 (2) 6 (5) 7 (5) 10 (11)
Duration of specialization, mean (S.D.), years 11 (5) 19 (5) 9 (3) 8 (2) 16 (7) 11 (6) 12 (6)
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novel anti-fibrotic therapies in clinical development [12],
this might become even more important for avoiding irre-
versible tissue damage. However, in this survey of phys-
icians, late presentation was reported to be common, with
more than half of patients having an mRSS515. This is
consistent with data from the prospective, observational
Pittsburgh Scleroderma Databank [13], where mean initial
mRSS was 2225 [13]. Moreover, physicians reported that
patients themselves delayed presentation due to a lack of
appreciation of their symptoms. This suggests that pa-
tients are a key audience for educational initiatives high-
lighting the importance of symptoms, such as RP, puffy
fingers and mild skin thickening, and the risk of progres-
sion to dcSSc.
The interviewed physicians considered that there was a
general lack of awareness of dcSSc, including presenting
symptoms, among primary HCPs. Some physicians also
reported that referral was further delayed due to waiting
lists. Primary HCPs are therefore also a key educational
audience to improve dcSSc awareness and facilitate ear-
lier referral to a rheumatologist or dermatologist, thereby
avoiding a delay in diagnosis. There may also be scope for
improved collaboration and communication between pri-
mary HCPs and specialists.
Once referred, the physicians were confident that a
rapid and accurate diagnosis was made. Diagnosis of
organ complications is also well established when pa-
tients are referred to specialists, further highlighting the
need for educational initiatives to focus on early recogni-
tion by patients and non-specialist HCPs. Notably,
the latest EULAR treatment recommendations are aimed
at different groups of physicians: rheumatologists
(for most organ manifestations), dermatologists (for
some milder manifestations in some countries) and
pulmonologists (for pulmonary arterial hypertension) [14].
Rheumatologists generally remain responsible for the
global management of patients after diagnosis, with
dermatologists having lesser involvement in diagnosis
and management.
Most physicians interviewed were unsatisfied with cur-
rent treatment options, particularly related to limiting organ
involvement and skin manifestations. There is therefore a
significant need for therapies that slow disease progres-
sion. Regarding disease evaluation and monitoring, many
physicians interviewed did not use the mRSS, often be-
cause of time constraints, although in some cases due to a
lack of awareness. Physicians should therefore be trained
in the use of such validated quantitative assessments to
improve the quality of care; more consistent use of the
mRSS may help to monitor disease progression. Several
studies, including prospective clinical trials, have shown
that the mRSS is a reliable tool for predicting disease out-
come [13, 15, 16].
The lack of a clear definition of specialist centres for
dcSSc should be addressed, as identification of such cen-
tres could improve patient care. Familiarity of physicians
in expert centres with the latest research and guidelines
ensures that the best possible care is given, and greater
understanding of disease processes and treatment
options is gained through experience in managing high
FIG. 1 Initial presentation of patients with dcSSc
Causes and location of the initial presentation of patients with dcSSc and the route to patient referral, as described by the
physicians interviewed. ER: emergency room; GI: gastrointestinal; IM: internal medicine physician.
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volumes of patients. There is also easier access to sup-
port networks from a variety of specialties.
This study was limited by the relatively small sample
size; however, as a first study in a rare indication, it was
designed to have qualitative validity—to provide an insight
into current behaviours of referring and treating physicians
across a range of practice settings. It is also important to
note that our findings are based on treating physicians’
perceptions of primary HCPs; no primary HCPs were
interviewed for this study, and therefore these findings
should be interpreted with caution. Future research may
benefit from including primary HCPs in the survey cohort.
In conclusion, unawareness of dcSSc symptoms among
patients and primary HCPs leads to late referral to specialist
care. Specialist centres for dcSSc are not well defined, and
their identification may lead to improved care. More consist-
ent use of validated tools, such as the mRSS, at diagnosis
and follow-up may help to monitor disease progression.
Acknowledgements
This study was carried out by Blueprint Partnership
(Manchester, UK), supported by Bayer AG (Berlin,
Germany). Editorial assistance was provided by Adelphi
Communications (Bollington, UK), supported by Bayer
AG. Bayer AG contributed to the study design and inter-
pretation of data.
Funding: This work was supported by Bayer AG.
Disclosure statement: O.D. had a consultancy relationship
and/or has received research funding from Actelion, Bayer,
BiogenIdec, Boehringer Ingelheim, ChemomAb, espeRare
foundation, Genentech/Roche, GlaxoSmithKline (GSK),
Inventiva, Italfarmaco, Lilly, medac, MedImmune, Mitsubishi
Tanabe Pharma, Pharmacyclics, Novartis, Pfizer, Sanofi,
Sinoxa and UCB in the area of potential treatments of sclero-
derma and its complications, and has a patent mir-29 for
the treatment of systemic sclerosis licensed. Y.A. consults for
Actelion, Bayer, Roche/Genentech, Inventiva, Medac, Pfizer,
Sanofi, Servier and UCB, and has received research grants
from Bristol-Myers Squibb (BMS), Roche/Genentech,
Inventiva, Pfizer, Sanofi and Servier. C.P.D. has undertaken
consultanacy to Bayer, Roche, GlaxoSmithKline, Actelion,
Inventiva, CSL Behring, Takeda, Merck-Serono,
Medimmune and Biogen, and has received research grants
from Actelion, GlaxoSmithKline, Novartis and CSL Behring.
B.H. is an employee of Bayer AG, Berlin, Germany. D.K. has
received investigator-initiated grants and acts as a consult-
ant to Actelion, Boehringer Ingelheim, BMS, Bayer, Corbus,
Cytori, GSK, Genentech/Roche, Sanofi and UCB, and owns
stocks in Eicos Sciences, Inc. J.P. consults for and/or has
research grants with Actelion, Bayer, BMS, Merck, Pfizer and
Roche. S.D. is an employee of Blueprint Partnership.
J.d.O.P. is an employee of Bayer. The other author has
declared no conflicts of interest.
Supplementary data
Supplementary data are available at Rheumatology online.
References
1 LeRoy EC, Black CF, Fleischmajer RF et al. Scleroderma
(systemic sclerosis): classification, subsets and patho-
genesis. J Rheumatol 1988;15:2025.
2 Nihtyanova SI, Schreiber BE, Ong VH et al. Prediction
of pulmonary complications and long-term survival
in systemic sclerosis. Arthritis Rheumatol 2014;66:
162535.
3 Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of
morbidity and mortality of systemic sclerosis in Canada.
Semin Arthritis Rheum 2010;39:26977.
4 Sampio-Barros PD, Bortoluzzo AB, Marangoni RG et al.
Survival, causes of death, and prognostic factors in systemic
sclerosis: analysis of 947 Brazilian patients. J Rheumatol
2012;39:19718.
5 Su R, Bennett M, Jacobs S et al. An analysis of connective
tissue disease-associated interstitial lung disease at a US
tertiary care center: better survival in patients with sys-
temic sclerosis. J Rheumatol 2011;38:693701.
6 Steen VD, Medsger TA Jr. Severe organ involvement in
systemic sclerosis with diffuse scleroderma. Arthritis
Rheum 2000;43:243744.
7 Denton CP, Hughes M, Gak N et al. BSR and BHPR
guideline for the treatment of systemic sclerosis.
Rheumatology 2016;55:190610.
8 Combe B, Landewe R, Daien CI et al. 2016 update of the
EULAR recommendations for the management of early
arthritis. Ann Rheum Dis 2017;76:94859.
9 Ereaut G. Analysis and interpretation in qualitative market
research. Chapter 5, Processes of ‘analysis’. London:
Sage Publications, 2002.
10 van den Hoogen F, Khanna D, Fransen J et al. 2013
classification criteria for systemic sclerosis: an American
College of Rheumatology/European League against
Rheumatism collaborative initiative. Arthritis Rheum
2013;65:273747.
11 Clements PJ, Lachenbruch PA, Ng SC et al. Skin score: a
semiquantitative measure of cutaneous involvement that
improves prediction of prognosis in systemic sclerosis.
Arthritis Rheum 1990;33:125663.
12 Khanna D, Distler JH, Sandner P, Distler O. Emerging
strategies for treatment of systemic sclerosis. J Scleroderm
Relat Dis 2016;1:18693.
13 Steen VD, Medsger TA Jr. Improvement in skin thickening
in systemic sclerosis associated with improved survival.
Arthritis Rheum 2001;44:282835.
14 Kowal-Bielecka O, Fransen J, Avouac J et al. Update of
EULAR recommendations for the treatment of systemic
sclerosis. Ann Rheum Dis 2017;76:132739.
15 Shand L, Lunt M, Nihtyanova S et al. Relationship be-
tween change in skin score and disease outcome in
diffuse cutaneous systemic sclerosis: application of a
latent linear trajectory model. Arthritis Rheum 2007;56:
242231.
16 Dobrota R, Maurer B, Graf N et al. Prediction of im-
provement in skin fibrosis in diffuse cutaneous systemic
sclerosis: a EUSTAR analysis. Ann Rheum Dis
2016;75:17438.
https://academic.oup.com/rheumatology 5
DcSSc referral, diagnosis and management
Downloaded from https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/kex504/4836310
by University of Zurich user
on 27 March 2018
